Document is current

Article History

Received: 22 November 2022

Accepted: 15 December 2022

First Online: 22 December 2022

Declarations

:

: Participants provided informed consent and data were treated according to current regulations. This study was approved by the Ethics Committee of IRCCS Istituto Auxologico Italiano (I.D.: 2013_06_25), by the Ethics Committee of Milano Niguarda Area 3 (I.D.: 393–09062021) and by the Ethics Committee of Istituti Clinici Scientifici Maugeri IRCCS (I.D.: CE 2495—12012021).

: V. S. received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., and Novartis Pharma AG, receives or has received research supports from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is on the Editorial Board of <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i>, <i>European Neurology</i>, <i>American Journal of Neurodegenerative Diseases</i>, <i>Frontiers in Neurology</i>. B.P. and L.C. received compensation for consulting services and/or speaking activities from Liquidweb S.r.l. B.P is Associate Editor for <i>Frontier in Neuroscience</i>. N. T. received compensation for consulting services from Amylyx Pharmaceuticals and Zambon Biotech SA. He is Associate Editor for Frontiers in Aging Neuroscience. C.L. received compensation for consulting services and/or speaking activities from Cytokinetics, Italfarmaco, and Mitsubishi Tanabe Pharma Europe. He is Associate Editor for <i>Frontiers in Neurology</i>. V.A.S. participates in Advisory Boards or teaching activities for Biogen, Roche, Avexis, PTC, Santhera, Sarepta, Dyne. S.W. receives licensing fees when the ALS Cognitive Behavioural Screen (ALS-CBS™) is used in pharmaceutical trials. J.M. is employed full time at Biogen; she does not receive compensations related to the ALS-CBS™. The remaining authors have nothing to declare.